パトジュリ

Tesmilifene

HCID 108092

基本情報

CAS
98774-23-3
標準SMILES
CCN(CC)CCOc1ccc(Cc2ccccc2)cc1
InChIKey
NFIXBCVWIPOYCD-UHFFFAOYSA-N
分子式
C19H25NO
平均分子量
283.4 g/mol
単同位体質量
283.19361442

概要

N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine is a diarylmethane.

名称と識別子

優先名称
Tesmilifene
IUPAC
2-(4-benzylphenoxy)-N,N-diethylethanamine
現地名
パトジュリ
英語名
Tesmilifene
分子式
C19H25NO
分子量
283.41

名称と別名

Tesmilifene98774-23-3DepmpetesmilifenoDTXSID1045661(2-(4-benzylphenoxy)ethyl)diethylamineI43T3ID6G2N,N-Diethyl-2-((4-phenylmethyl)phenoxy)ethanaminen,n-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamineDTXCID9025661[2-(4-benzylphenoxy)ethyl]diethylamineN,N-diethyl-2-(4-(phenylmethyl)phenoxy)ethanamine
名称をさらに表示
DPPEN,N-Diethyl-2-(4-benzylphenoxy)ethanamineMarquisCS-1155Pato beadTesmilifineUnii-I43T3id6G2Patozuli 98774-23-3
tesmilifenumRefChem:1883162-(4-benzylphenoxy)-N,N-diethylethanamineTesmilifene [INN]N,N-DIETHYL-2-[4-BENZYLPHENOXY]ETHANAMINECHEMBL26424Ethanamine, N,N-diethyl-2-(4-(phenylmethyl)phenoxy)-NCGC00024762-02

データベース識別子

CAS
98774-23-3
PubChem CID
108092
DTXSID
DTXSID1045661
ChEMBL
CHEMBL26424
ChEBI
CHEBI:93414
UNII
I43T3ID6G2
Nikkaji
J582.987I

物性

構造計算による物性

XLogP
4.6
極性表面積
12.5 Ų
水素結合供与体数
0
水素結合受容体数
2
回転可能結合数
8
重原子数
21

実験および物理化学的性質

DrugsPharmaceuticals -> Listed in ZINC15

物理化学的性質

沸点
397 · 397 ºC
比重(密度)
1.002 · 1.002
闪点
117 · 117 ºC
貯蔵温度
2 · 2-8°C
酸解離定数(Pka)
9 · 9+-.0.25(Predicted)
InChI
InChI=1S/C19H25NO/c1-3-20(4-2)14-15-21-19-12-10-18(11-13-19)16-17-8-6-5-7-9-17/h5-13H,3-4,14-16H2,1-2H3

安全と法規制

安全データ

注意喚起語
警告
危険有害性情報
コード 危険有害性情報 危険有害性クラス 区分 注意喚起語 シンボル P コード H302

化学と産業

薬理情報

Mechanism of Action · 1 件

Although the exact mechanism of action is not known, one study (PMID: 16413681) proposes that tesmilifene may be an activating p-gp substrate, which enables the p-gp pump to extrude typical p-gp substrates (such as anthracyclines or taxanes) more efficiently. This process consumes ATP, since the p-gp is absolutely, and highly dependent on ATP hydrolysis. The mechanism of cell death is likely to result not from the presence of chemotherapy inside the cell (in fact the chemotherapy is extruded) but, directly or indirectly, from the enhanced consumption of ATP. The ATP may be consumed below a threshold necessary for survival, or, (more likely) the enhanced ATP production required to maintain ATP levels may result in the generation of reactive oxygen species (ROS) to an extent that overwhelms the cell’s ability to inactivate them. The result would be additional cell death, but only in the mdr+ population. The doxorubicin would continue to act on the drug sensitive remainder of the cell population, but without the help of tesmilifene.

Metabolism/MetabolitesHepatic
MeSH Pharmacological Classification · 2 件

Drugs that bind to but do not activate histamine receptors, thereby blocking the actions of histamine or histamine agonists. Classical antihistaminics block the histamine H1 receptors only.

Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.

サプライヤー81 社

北京华美互利生物化工010-56205725 · [email protected]
湖北永阔科技有限公司027-59223108 15972152991 · [email protected]
Shanghai Biolang Biotechnology Co., Ltd.+86-15970428662 +86-13397199602 · [email protected]
湖北威德利化学试剂有限公司181-6332-1995 18062128043 · [email protected]
武汉英诺医药科技有限公司+86-027-59232304 15387063101 · [email protected]

関連反応

0 件

現在のフィルター条件では反応記録がありません。

化合物ノート

読み込み中…